Issue link: http://osercommunicationsgroup.uberflip.com/i/265897
C h a i n D r u g s t o r e D a i l y M o n d a y, A u g u s t 1 2 , 2 0 1 3 5 0 company. TD: QS/1 provides healthcare technolo- gy solutions for pharmacies and HME businesses. Providing management solu- tions to pharmacies since 1977, we pro- vide the industry's broadest array of tech- nology and services to automate the entire store while providing central man- agement and control chain-wide. CDD: To what do you owe QS/1's suc- cess? TD: We focus entirely on our customers. We put a lot of time and effort into under- standing what pharmacies need to be suc- cessful, whether it's more efficient man- agement of the front end or, as is more and more the case, developing and man- aging services that enhance the pharma- cy's service to its customers. It's all made possible by a great team of hard-working, talented employees. CDD: What do you think makes QS/1's products and services unique? TD: The primary advantage is that we bring the entire business together with one integrated solution. No other compa- ny offers the array of technology and services that we do to connect a store's various profit centers while providing complete control by the company's head- quarters. Our technology and services work together seamlessly. Also, we develop our products and solutions with much input from our customers. CDD: What new products or services are or will be available from QS/1 over the next year? TD: We've just incorporated Medicare Part B compliance documentation into our pharmacy management systems – becoming the only system with that increasingly important feature. We've released mobile apps for Android and iPhone smartphones, as well as portable checkout via a tablet. We were also one of the first pharmacy vendors to receive certification for Electronic Prescriptions for Controlled Substances (EPCS). CDD: What do you anticipate to be chain pharmacy's greatest challenge in the year ahead? TD: One thing is determining how they can manage additional services such as Medication Therapy Management (MTM) and adherence. Pharmacy is quickly expanding beyond dispensing, and the chains will want to take advan- tage of that. CDD: What do you see being the hottest technology products for chain pharmacy this year? TD: Automation in general will be very important. Pharmacies are look- ing for tools to help do more work more efficiently. Automated dispens- ing may be the hottest item in the industry – particularly robots like our sister company's RxMedic ADS ® and RM64 ® products. Communication products are also becoming more important. Pharmacies need tools that facilitate communication with their customers – mobile prescription capa- bility, texting, etc. CDD: What would you like pharmacists at NACDS to look for at your booth? TD: The most important reason to visit is to see how much truly integrating the entire business with one system can improve productivity, customer service, and profitability. No other company truly integrates the entire store. We manage everything from workflow to will call seamlessly while providing headquarters with the real- time control they need. For more information, visit QS/1 at booth 5008, call 800-231-7776 or go online to www.qs1.com. QS/1 (Cont'd. from p. 1) Precision Dose, Inc. This is Precision Dose's 10th year of operation, focusing on the hospital and institutional markets with a broad portfolio of liquid products in a unit dose format. TAGI was set up as a separate entity in order to provide the focus required to successfully penetrate the retail segment with a product portfo- lio derived from licensing, acquisition and development activities. CDD: What would you say makes your company unique? TA: TAGI and Precision Dose as a combined entity places us in a unique position to take advantage of available generic product opportunities across all customer segments. CDD: Are you introducing any new products? TA: To date in 2013, we have launched Alendronate Sodium Oral Solution, the only FDA Orangebook AA-rated generic to Fosamax ® oral solution, the Phentermine 30mg and 15mg capsule products and the Codeine Sulfate Oral Solution unit dose line extension for Precision Dose's hospital seg- ment. In the remainder of this year, we expect to introduce two additional generic products and 2 unit dose line extensions that will be marketed through Precision's Dose. CDD: Tell our readers about your trade show objectives, plans, products, promo- tions, etc. TA: We will be communicating with cur- rent and potential customers of TAGI Pharma about business opportunities around products launched as well as in our pipeline. In addition, we will be reviewing our programs to drive movement of those products through our distribution and retail partners, utilizing telemarketing activities, stocking programs, and social media initiatives to create demand. CDD: To what do you attribute your company's success? TA: A thorough understanding of the mar- kets we compete and identification of prof- itable product opportunities, which pro- vides a significant value-add with our prod- uct development and manufacturing part- ners. In addition, we ensure product quality and high service level performance that drives customer loyalty. Finally, the ability to leverage the Precision Dose Operation and Administrative infrastructure, allowing us to invest more in product licensing, acquisition and development activities. CDD: How can our readers find out more about your company? TA: For general information on TAGI Pharma and our product portfolio, visit our web site www.tagipharma.com, or call our customer support group at 855-225- 8244 or 815-624-7685. For questions related to establishing a business relation- ship with TAGI Pharma, call Kenny Harrington (Vice President of Sales & Marketing) at 815-624-8523 ext. 203. For more information, visit booth 4917, go online to www.tagipharma.com, call 855-225-8244 or email market- ing@tagipharma.com. TAGI Pharma (Cont'd. from p. 1) ABBOTT MEDICAL OPTICS: DEDICATED TO IMPROVING THE QUALITY OF LIFE With aging populations worldwide, vision care is a growing area of patient need. Abbott is a leader in vision care with a long history of innovation and market-leading vision correction tech- nologies. Abbott's products and services address a wide range of vision disorders and meet the needs of patients who seek greater freedom from the limitations of eyeglasses. Abbott offers the widest range of proven refractive technologies for patients with myopia (near-sightedness), hyperopia (farsightedness),astigmatism (condition that causes blurred vision), presbyopia (diminished ability to focus on near objects) cataract, spherical aberration (diffi- culty focusing) and corneal health. Abbott's proven programs and systems help eye care professionals address vision care chal- lenges and master refractive technologies. Globally, Abbott is No. 1 in LASIK and No. 2 in cataract (where it is growing its position with the Tecnis platform) and No. 3 in eye care solu- tions. Abbot's Vision Care pipeline is balanced across each segment, with a number of products launching over the next five years. The global demand for vision care is on the rise, as the baby boomer population ages and vision care becomes more affordable in less- developed countries. Geographically, 65 percent of Abbott's Vision Care sales are generated outside the United States, with further expansion under- way in emerging markets such as China and India. Abbott's vision care business employs more than 3,700 people worldwide and has a presence in more than 60 countries. Abbott is the world's leading provider of laser vision correction (LASIK) technologies. The complete line of refractive products meets the needs of patients who seek freedom from eye- glasses or contact lenses. Abbott offers eye care professionals the industry's most advanced laser vision technologies to correct myopia, hyperopia, and astig- matism and to enhance surgeon produc- tivity. Key Products WaveScan WaveFront System: Captures unique imperfections in each patient's eyes and creates a personal- ized treatment plan. iFS Femtosecond Laser: Focuses a beam of light below the surface of the cornea to create the corneal flap before a LASIK treatment is performed. STAR S4 IR Excimer Laser System: Computer-driven laser that corrects refractive errors by reshaping the cornea. Advanced CustomVue Procedure: Custom LASIK procedure that corrects unique imperfections in each patient's eyes and is capable of treating the indus- try's broadest range of refractive condi- tions. For more information, visit booth 2849 or go online to www.abbott medicaloptics.com. PET HEAD FEATURES DOGS LUV IT! DRY SHAMPOO Pet Head is an edgy, fashion-forward pet product line that is the standard of cool, that guarantees to enhance the interaction between you and your pet. So fun and "entertailing," it makes an emotional connection, giving the consumer the need to buy and love Pet Head. Pet Head is only for cool pets, for pets that rock and yes, fun times are guaranteed! Featuring at NACDS is Pet Head's Dogs Luv It! Dry Shampoo with strawberry lemonade fragrance is a fast, easy and on-the-go clean. The consumer has come to under- stand the ease, convenience and results of a dry shampoo—it will be an effortless yet innovative entry into the pet care category. Spray it on, rub it into the coat, and go! Use up to two times in between bathing and grooming. Your dog will be so happy with no water fuss! For further information, contact Steve Austin at 310 977 3028, go to www.pet- head.com or visit booth 5057.